Healthpeak Properties Analyst Price Targets

Wall Street analyst price targets and consensus rating for Healthpeak Properties (DOC).

Price Target Range — 12 Quarters

Analyst Consensus — 19 Analysts

7Buy

12Hold

Consensus RatingNeutral# Analysts19Avg. Consensus PT$21Upside to Avg. PT+2.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 21, 2026	Evercore ISI Group	James Kammert	PT Cut	In-Line	$23→$22
Sep 15, 2026	Jefferies	Joe Dickstein	Assumes	Hold	$22→$21
Aug 31, 2026	Barclays	Richard Hightower	PT Raise	Equal-Weight	$23→$24
Aug 13, 2026	Baird	Amanda Sweitzer	PT Raise	Outperform	$21→$24
Aug 11, 2026	Citigroup	Nick Joseph	PT Raise	Neutral	$20→$22
Aug 10, 2026	RBC Capital	Michael Carroll	PT Raise	Outperform	$21→$24
Aug 6, 2026	Cantor Fitzgerald	Richard Anderson	PT Raise	Neutral	$20→$23
Jul 15, 2026	Wells Fargo	John Kilichowski	PT Raise	Equal-Weight	$20→$22
Jul 8, 2026	UBS	—	PT Raise	Neutral	$19→$22
Jul 7, 2026	Barclays	Richard Hightower	Initiate	Overweight→Equal-Weight	$23
Jul 6, 2026	Mizuho	Vikram Malhotra	PT Raise	Outperform	$21→$24
Jun 24, 2026	JP Morgan	Michael Mueller	PT Raise	Neutral	$18→$21
Jun 17, 2026	Raymond James	David Rodgers	Reinstates	Outperform→Market Perform	—
Jun 15, 2026	BMO Capital	Juan Sanabria	PT Raise	Outperform	$20→$24
Jun 11, 2026	Morgan Stanley	Richard Hill	Downgrade	Overweight→Equal-Weight	$20→$22
Jun 1, 2026	Wells Fargo	John Kilichowski	PT Raise	Equal-Weight	$18→$20
May 27, 2026	Scotiabank	Nicholas Yulico	PT Raise	Sector Perform	$19→$21
May 22, 2026	Morgan Stanley	Richard Hill	PT Raise	Overweight	$18→$20
May 14, 2026	RBC Capital	Michael Carroll	PT Raise	Outperform	$20→$21
May 13, 2026	UBS	—	PT Raise	Neutral	$17→$19

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Evercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

Evercore ISI Group analyst James Kammert maintains Healthpeak Properties (NYSE:DOC) with a In-Line and lowers the price target from $23 to $22.

Benzinga Newsdesk

PRO
Jefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

Jefferies analyst Joe Dickstein assumes Healthpeak Properties (NYSE:DOC) with a Hold rating and lowers Price Target of $21.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

Barclays analyst Richard Hightower maintains Healthpeak Properties (NYSE:DOC) with a Equal-Weight and raises the price target from $23 to $24.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

In uncertain markets, investors turn to dividend-yielding stocks. Benzinga provides latest analyst ratings & news for high-yielding stocks.

Avi Kapoor

PRO
Baird Maintains Outperform on Healthpeak Properties, Raises Price Target to $24

Baird analyst Amanda Sweitzer maintains Healthpeak Properties (NYSE:DOC) with a Outperform and raises the price target from $21 to $24.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Healthpeak Properties, Raises Price Target to $22

Citigroup analyst Nick Joseph maintains Healthpeak Properties (NYSE:DOC) with a Neutral and raises the price target from $20 to $22.

Benzinga Newsdesk

Healthpeak Properties Inc

Healthpeak Properties Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Evercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

PRO
Jefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

PRO
Baird Maintains Outperform on Healthpeak Properties, Raises Price Target to $24

PRO
Citigroup Maintains Neutral on Healthpeak Properties, Raises Price Target to $22

People Also Watch

People Also Watch

Healthpeak Properties Inc

Healthpeak Properties Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROEvercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

PROJefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

PROBarclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

PROBaird Maintains Outperform on Healthpeak Properties, Raises Price Target to $24

PROCitigroup Maintains Neutral on Healthpeak Properties, Raises Price Target to $22

People Also Watch

People Also Watch

PRO
Evercore ISI Group Maintains In-Line on Healthpeak Properties, Lowers Price Target to $22

PRO
Jefferies Assumes Healthpeak Properties at Hold, Lowers Price Target of $21

PRO
Barclays Maintains Equal-Weight on Healthpeak Properties, Raises Price Target to $24

PRO
Baird Maintains Outperform on Healthpeak Properties, Raises Price Target to $24

PRO
Citigroup Maintains Neutral on Healthpeak Properties, Raises Price Target to $22